New management taking charge at Geistlich Pharma
Wolhusen LU – On July 1, Ralf P. Halbach will be joining Geistlich Pharma as the new CEO. He is succeeding Paul Note, who is retiring. Directors Rolf Jeger and Terance Hart have likewise opted to enter retirement.
Geistlich Pharma, which forms part of the Schlieren-based Geistlich Group, will be under new management from July 1 onwards, with Ralf P. Halbach set to replace Paul Note as CEO. After 15 years leading the company, Note is taking a well-earned retirement. His period in charge has been “characterized by expansion”, according to a press release issued by the Board of Directors of Geistlich Pharma AG. Under Note’s leadership, a global structure with numerous affiliates was established, which has allowed Geistlich to position itself as a supplier of regenerative products with innovative concepts. Over this time, the Geistlich Pharma team grew from 140 employees to more than 700.
Alongside Note, both Rolf Jeger (Director for Governance, Risk and Compliance) and Terance Hart (Director Research) played a key role in this expansion. They worked for 12 and 11 years respectively at Geistlich Pharma.
The new CEO Ralf P. Halbach was born and raised in Barcelona, Spain, although holds both Swiss and German nationality. He has a doctorate in Organic Chemistry from the University of Basel and an MBA from INSEAD, a private business school in France.
According to the press release, Halbach will bring more than 25 years of international experience in the pharmaceutical and diagnostic sector to the table in his new role with Geistlich Pharma. Over the past ten years, Halbach worked for Roche in several functions and across various departments and regions. He has held positions in global strategic marketing in the USA and regional commercial functions in Northwest Africa, Southeast Asia and Central Europe. Prior to this, he worked as a General Manager for two pharmaceutical start-ups.
Geistlich Pharma specializes in the development of bio-materials for the regeneration of bones, cartilage and tissue.
